A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1743-422X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma ; volume:8 ; number:1 ; day:10 ; month:6 ; year:2011 ; pages:1-12 ; date:12.2011
Virology journal ; 8, Heft 1 (10.6.2011), 1-12, 12.2011
- Creator
-
Takaoka, Hiroo
- Contributor
-
Takahashi, Gen
Ogawa, Fumi
Imai, Tomoaki
Iwai, Soichi
Yura, Yoshiaki
SpringerLink (Online service)
- DOI
-
10.1186/1743-422X-8-294
- URN
-
urn:nbn:de:1111-201605013451
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takaoka, Hiroo
- Takahashi, Gen
- Ogawa, Fumi
- Imai, Tomoaki
- Iwai, Soichi
- Yura, Yoshiaki
- SpringerLink (Online service)
Other Objects (12)
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic Virotherapy of Neuroendocrine Neoplasms with the Vaccinia virus GLV-1h68 and the Herpes simplex virus T-VEC
Immune checkpoint modulation enhances oncolytic virotherapy
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma
Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic Virotherapy of Neuroendocrine Neoplasms with the Vaccinia virus GLV-1h68 and the Herpes simplex virus T-VEC
Immune checkpoint modulation enhances oncolytic virotherapy
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma
Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Oncolytic herpes simplex virus and immunotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic Virotherapy of Neuroendocrine Neoplasms with the Vaccinia virus GLV-1h68 and the Herpes simplex virus T-VEC
Immune checkpoint modulation enhances oncolytic virotherapy
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma
Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy